Absco Therapeutics (AbscoTx)

Absco Therapeutics (AbscoTx) has developed an image-guided, injectable intratumoral drug delivery platform designed to modify the tumor microenvironment and train the immune system to combat solid tumors, with an initial focus on cervical cancer due to promising clinical proof of concept with the lead API in that setting. The company uses a proprietary thermoresponsive polymer with an additive that enables real-time imaging for precise delivery. The platform’s ability to solidify within the tumor for controlled, long-term drug release, combined with real-time confirmation of accurate placement, distinguishes it from previous intratumoral therapies that have struggled with drug leakage and the need for repeat injections.